Group items tagged
Treatments for Basal Cell Carcinoma - 0 views
Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2008 Nov-Dec] - ... - 0 views
-
The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - better choices, be... - 0 views
Aldara - About sBCC - 0 views
21152128[PMID] - PMC result - 0 views
-
Nodulo-cystic BCC. [Image, Photograph] Venura Samarasinghe, et al. J Skin Cancer. 2011;2011:328615.
Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream | Alessi SS, et al | CLIN... - 0 views
-
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
-
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
Imiquimod 5% cream for the treatment of superficia... [J Am Acad Dermatol. 2004] - PubM... - 0 views
-
Composite clearance rates (combined clinical and histological assessments) for the 5 and 7x/week imiquimod groups were 75% and 73%, respectively. Histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. Increasing severity of erythema, erosion, and scabbing/crusting was associated with higher clearance rates. CONCLUSION: Imiquimod appears to be safe and effective for the treatment of sBCC when compared with vehicle cream. The difference in clearance rates between the two imiquimod dosing groups was not significant. The 5x/week regimen is recommended.
Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views
-
Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
Two-year interim results from a 5-year study evalu... [Australas J Dermatol. 2006] - Pu... - 0 views
-
The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
New Skin Cancer Treatment Approved - Skin Diseases, Conditions, Symptoms, and Procedure... - 0 views
-
79% of patients had no evidence of their sBCC at two years after finishing treatment.
Nonsurgical Treatment Options for Basal Cell Carcinoma | Review Article | Journal of Sk... - 0 views
-
Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.
Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream - 0 views
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
‹ Previous
21 - 40 of 60
Next ›
Showing 20▼ items per page